FDA expands authorisation of two monoclonal antibodies for treatment and post-exposure prevention of COVID-19 to paediatric patients Read more
SPARC enters into licensing agreement with Biomodifying to acquire exclusive rights for antibody against unique oncology target Read more
GSK and Oxford University announce Oxford-GSK Institute of Molecular and Computational Medicine Read more